Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

Antoni, Christian; Krueger, Gerald G.; Vlam, Kurt de; Birbara, C.; Beutler, Anna; Guzzo, Cynthia; Zhou, Bei; Dooley, Lisa T.; Kavanaugh, Arthur

doi:10.1136/ard.2004.032268

Cited by 651 publications

(521 citation statements)

References 28 publications

Supporting

Mentioning

472

Contrasting

Unclassified

Order By: Relevance

“…While anti-TNF agents improve outcomes in PsA, [3][4][5][6][7] many patients still experience inadequate disease control and/or are intolerant of these agents. Loss of response over time is also clinically problematic.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 Pathogenesis-based interventions, particularly therapies targeting tumor necrosis factor (TNF), have improved outcomes in PsA patients. [3][4][5][6][7] Recently, the interleukin (IL)-12/23 inhibitor ustekinumab and the phosphodiesterase-4 inhibitor apremilast have also demonstrated efficacy. [8][9][10] Despite this progress, not all patients respond to or tolerate therapy, and significant unmet clinical needs remain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The study was an analysis of most patients in the previously published phase II and III of the randomized placebo-controlled trials of infliximab in PsA (Infliximab Multinational Psoriatic Arthritis Controlled Trial [IMPACT] and the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2 [IMPACT 2]) (12,13). In both studies, patients with active PsA were treated with infliximab (5 mg/kg) or placebo followed by blinded infliximab treatment through week 46 and open-label infliximab treatment from weeks 50 -98 in IMPACT.…”

Section: Methodsmentioning

confidence: 99%

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

Coates¹,

Helliwell²

2010

Arthritis Care & Research

217

132

View full text Add to dashboard Cite

Objective. New criteria for minimal disease activity (MDA) in psoriatic arthritis (PsA) have been developed. The aim is to provide further validation of these criteria using data obtained in interventional trials with infliximab, a drug with proven efficacy in PsA. Methods. The data were obtained from patients in phase II and III infliximab studies of PsA. In both studies, patients with active PsA were treated with infliximab (5 mg/kg) or placebo followed by a period of treatment with infliximab. Between-group comparisons in terms of those achieving MDA and the relationship of MDA to American College of Rheumatology outcomes, C-reactive protein levels, and radiologic progression were performed.

show abstract

“…Levels of TNF and IL‐17A–producing CD8+ T cells are elevated in the synovial fluid of patients with PsA 4, 9. Inhibition of either TNF or IL‐17A alone has demonstrated efficacy in improving joint inflammation, features of skin disease, and quality of life in patients with PsA 10, 11, 12, 13, 14, 15, 16, suggesting that TNF and IL‐17A may both contribute to the pathophysiology of PsA. An unanswered question has been whether, assuming that the contributions of TNF and IL‐17A are at least partly independent of one another, dual neutralization of TNF and IL‐17A may provide the opportunity to achieve better control of inflammation in patients with PsA compared to neutralization of either target alone.…”

mentioning

confidence: 99%

“…The treatment of PsA with a combination of 2 conventional disease‐modifying antirheumatic drugs (DMARDs) 20, 21 or a DMARD plus a TNF inhibitor has been reported 10, 11, 15, 22. However, clinical trials simultaneously inhibiting 2 cytokines, TNF and IL‐17A, with biologics have not been reported in patients with PsA.…”

mentioning

confidence: 99%

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

Mease

Genovese

Weinblatt

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

ObjectiveTo investigate the safety and efficacy of ABT‐122, a tumor necrosis factor (TNF)– and interleukin‐17A (IL‐17A)–targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate.MethodsPatients (n = 240) were randomized to receive ABT‐122 (120 or 240 mg every week), adalimumab (40 mg every other week), or placebo in a 12‐week double‐blind, parallel‐group study. The primary efficacy end point was the proportion of patients achieving ≥20% improvement in disease activity according to the American College of Rheumatology response criteria (ACR20) at week 12. Secondary and exploratory 12‐week end points included 50% improvement (ACR50) and 70% improvement (ACR70) response rates, and proportion of patients meeting the Psoriasis Area and Severity Index (PASI) response criteria for ≥75% (PASI75) and ≥90% (PASI90) improvement in skin scores among those with ≥3% of their body surface area affected by psoriasis.ResultsIn both ABT‐122 dose groups, ACR20 response rates at week 12 (64.8–75.3%) were superior to that in patients receiving placebo (25.0%) (P < 0.001) but similar to that in patients receiving adalimumab (68.1%). ACR50 and ACR70 response rates were also superior in both ABT‐122 dose groups (36.6–53.4% and 22.5–31.5%, respectively) compared to the placebo group (12.5% and 4.2%, respectively) (P < 0.05). Among eligible patients in the placebo, adalimumab, ABT‐122 120 mg every week, and ABT‐122 240 mg every week treatment groups, PASI75 responses were achieved in 27.3%, 57.6%, 74.4%, and 77.6% of patients, respectively, whereas PASI90 responses were achieved in 18.2%, 45.5%, 48.8%, and 46.9% of patients, respectively. Frequencies of treatment‐emergent adverse events, including infections, were similar across all treatment groups, causing no discontinuations. No serious infections or systemic hypersensitivity reactions were reported with ABT‐122.ConclusionDual neutralization of TNF and IL‐17A with ABT‐122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12‐week treatment course in patients with PsA.

show abstract

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

Cited by 651 publications

References 28 publications

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

Contact Info

Product

Resources

About